Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Cancer Cell|May 23, 2020
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor ActivityXiaojie Yu, H T Claude Chan, Hayden Fisher, et al.Communications Biology|June 24, 2021
TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activityXiaojie Yu, Sonya James, James H Felce, et al.Cancer Cell|March 27, 2018
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 AntibodiesXiaojie Yu, H T Claude Chan, Christian M Orr, et al.Blood|March 13, 2010
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionStephen A Beers, Ruth R French, H T Claude Chan, et al.Blood|July 20, 2011
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacySean H Lim, Andrew T Vaughan, Margaret Ashton-Key, et al.JCI Insight|September 2, 2020
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulationMuchaala Yeboah, Charys Papagregoriou, Des C Jones, et al.Cell Reports|July 20, 2022
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanismsAlexander P Simpson, Ali Roghanian, Robert J Oldham, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White, Lang Dou, H T Claude Chan, et al.Cancer Immunology Research|September 26, 2025
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for ImmunotherapyKirstie L S Cleary, Monika Semmrich, Linda Martensson, et al.Cancer Cell|December 16, 2014
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodiesAnn L White, H T Claude Chan, Ruth R French, et al.Pageof 4